Supernus Pharmaceuticals, Inc. (SUPN) Earnings History
Net Loss18 years of earnings data (2008–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Supernus Pharmaceuticals, Inc. (SUPN) Earnings Overview
As of June 22, 2026, Supernus Pharmaceuticals, Inc. (SUPN) reported trailing twelve-month net income of -$29M, reflecting -151.5% year-over-year growth. The company earned $-0.50 per diluted share over the past four quarters, with a net profit margin of -5.4%.
Looking at the long-term picture, SUPN's historical earnings data spans multiple years. The company achieved its highest annual net income of $127M in fiscal 2020.
Supernus Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PCRX ($9M net income, 1.0% margin), ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), SUPN has room to improve margins relative to the peer group. Compare SUPN vs PCRX →
SUPN Earnings vs Peers
Earnings metrics vs comparable public companies
SUPN Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | -152.2% | -$37M | $-0.68 | -5.4% | -5.1% |
| 2024 | $74M | +5512.8% | $82M | $1.32 | 11.2% | 12.3% |
| 2023 | $1M | -97.8% | -$5M | $0.02 | 0.2% | -0.9% |
| 2022 | $61M | +13.6% | $46M | $1.04 | 9.1% | 6.9% |
| 2021 | $53M | -57.9% | $86M | $0.98 | 9.2% | 14.8% |
| 2020 | $127M | +12.3% | $174M | $2.36 | 24.4% | 33.4% |
| 2019 | $113M | +1.9% | $149M | $2.10 | 28.8% | 37.8% |
| 2018 | $111M | +93.8% | $144M | $2.05 | 27.1% | 35.3% |
| 2017 | $57M | -37.2% | $100M | $1.08 | 19.0% | 32.9% |
| 2016 | $91M | +550.8% | $54M | $1.76 | 42.4% | 25.2% |
| 2015 | $14M | -29.5% | $18M | $0.28 | 9.7% | 12.2% |
| 2014 | $20M | +121.5% | $24M | $0.32 | 16.3% | 19.9% |
| 2013 | -$92M | -99.4% | -$62M | $-2.90 | -767.7% | -515.2% |
| 2012 | -$46M | -182.6% | -$42M | $-2.65 | -3127.3% | -2849.3% |
| 2011 | $56M | +245.6% | -$38M | $3.64 | 6974.2% | -4701.4% |
| 2010 | -$38M | -8461.5% | -$40M | $-2.78 | -36285.8% | -37851.9% |
| 2009 | $460,000 | +101.4% | $4M | $-0.21 | 1.2% | 10.6% |
| 2008 | -$33M | - | -$26M | $-2.42 | -376.7% | -290.9% |
Download Data
Export SUPN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
What is SUPN earnings per share (EPS)?
SUPN trailing twelve-month (TTM) diluted EPS is $-0.50, reflecting -151.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.
What is Supernus Pharmaceuticals, Inc.'s net income?
Supernus Pharmaceuticals, Inc. (SUPN) trailing twelve-month net income is $-29M as of 2025. Earnings declined -151.5% year-over-year.
Is SUPN profitable?
SUPN is not currently profitable on a TTM basis, reporting a net loss of $-29M. Net margin is -5.4%. Investors should monitor for a return to profitability.
What is SUPN's earnings growth rate?
SUPN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.
What are SUPN's profit margins?
Supernus Pharmaceuticals, Inc. net profit margin is -5.4%, operating margin is -5.1%, and gross margin is +89.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -3.7%.
Is SUPN growing earnings?
SUPN earnings are declining — EPS fell -151.5% year-over-year. TTM net income dropped to $-29M. This contrasts with the 5-year CAGR of N/A.
What was SUPN's best earnings year?
Supernus Pharmaceuticals, Inc.'s highest annual net income on record is $127M, achieved in fiscal year 2020. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.
What were SUPN's earnings last quarter?
SUPN's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.